Literature DB >> 29588429

Hydroxyproline Metabolism and Oxalate Synthesis in Primary Hyperoxaluria.

Sonia Fargue1, Dawn S Milliner2, John Knight1, Julie B Olson2, W Todd Lowther3, Ross P Holmes4.   

Abstract

Background Endogenous oxalate synthesis contributes to calcium oxalate stone disease and is markedly increased in the inherited primary hyperoxaluria (PH) disorders. The incomplete knowledge regarding oxalate synthesis complicates discovery of new treatments. Hydroxyproline (Hyp) metabolism results in the formation of oxalate and glycolate. However, the relative contribution of Hyp metabolism to endogenous oxalate and glycolate synthesis is not known.Methods To define this contribution, we performed primed, continuous, intravenous infusions of the stable isotope [15N,13C5]-Hyp in nine healthy subjects and 19 individuals with PH and quantified the levels of urinary 13C2-oxalate and 13C2-glycolate formed using ion chromatography coupled to mass detection.Results The total urinary oxalate-to-creatinine ratio during the infusion was 73.1, 70.8, 47.0, and 10.6 mg oxalate/g creatinine in subjects with PH1, PH2, and PH3 and controls, respectively. Hyp metabolism accounted for 12.8, 32.9, and 14.8 mg oxalate/g creatinine in subjects with PH1, PH2, and PH3, respectively, compared with 1.6 mg oxalate/g creatinine in controls. The contribution of Hyp to urinary oxalate was 15% in controls and 18%, 47%, and 33% in subjects with PH1, PH2, and PH3, respectively. The contribution of Hyp to urinary glycolate was 57% in controls, 30% in subjects with PH1, and <13% in subjects with PH2 or PH3.Conclusions Hyp metabolism differs among PH types and is a major source of oxalate synthesis in individuals with PH2 and PH3. In patients with PH1, who have the highest urinary excretion of oxalate, the major sources of oxalate remain to be identified.
Copyright © 2018 by the American Society of Nephrology.

Entities:  

Keywords:  genetic renal disease; hydroxyproline; kidney stones; metabolism; oxalate; primary hyperoxaluria

Mesh:

Substances:

Year:  2018        PMID: 29588429      PMCID: PMC6054332          DOI: 10.1681/ASN.2017040390

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  33 in total

1.  L-glyceric aciduria. A new genetic variant of primary hyperoxaluria.

Authors:  H E Williams; L H Smith
Journal:  N Engl J Med       Date:  1968-02-01       Impact factor: 91.245

2.  The metabolism of collagen and its hormonal control in the rat with special emphasis on the interactions of collagen and calcium in the bones.

Authors:  O Laitinen
Journal:  Acta Endocrinol (Copenh)       Date:  1967

3.  Modeling of hyperoxaluric calcium oxalate nephrolithiasis: experimental induction of hyperoxaluria by hydroxy-L-proline.

Authors:  S R Khan; P A Glenton; K J Byer
Journal:  Kidney Int       Date:  2006-07-19       Impact factor: 10.612

4.  Hydroxyproline ingestion and urinary oxalate and glycolate excretion.

Authors:  J Knight; J Jiang; D G Assimos; R P Holmes
Journal:  Kidney Int       Date:  2006-10-04       Impact factor: 10.612

5.  Identification and expression of a cDNA for human hydroxypyruvate/glyoxylate reductase.

Authors:  G Rumsby; D P Cregeen
Journal:  Biochim Biophys Acta       Date:  1999-09-03

6.  Mutations in DHDPSL are responsible for primary hyperoxaluria type III.

Authors:  Ruth Belostotsky; Eric Seboun; Gregory H Idelson; Dawn S Milliner; Rachel Becker-Cohen; Choni Rinat; Carla G Monico; Sofia Feinstein; Efrat Ben-Shalom; Daniella Magen; Irith Weissman; Celine Charon; Yaacov Frishberg
Journal:  Am J Hum Genet       Date:  2010-09-10       Impact factor: 11.025

7.  Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis.

Authors:  Carla G Monico; Sandro Rossetti; Ruth Belostotsky; Andrea G Cogal; Regina M Herges; Barbara M Seide; Julie B Olson; Eric J Bergstrahl; Hugh J Williams; William E Haley; Yaacov Frishberg; Dawn S Milliner
Journal:  Clin J Am Soc Nephrol       Date:  2011-09       Impact factor: 8.237

8.  Genetic cause and prevalence of hydroxyprolinemia.

Authors:  Christian Staufner; Tobias B Haack; Patrik Feyh; Gwendolyn Gramer; Deepthi Ediga Raga; Caterina Terrile; Sven Sauer; Jürgen G Okun; Junmin Fang-Hoffmann; Ertan Mayatepek; Holger Prokisch; Georg F Hoffmann; Stefan Kölker
Journal:  J Inherit Metab Dis       Date:  2016-05-02       Impact factor: 4.982

9.  Inhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1.

Authors:  Chaitali Dutta; Nicole Avitahl-Curtis; Natalie Pursell; Marita Larsson Cohen; Benjamin Holmes; Rohan Diwanji; Wei Zhou; Luciano Apponi; Martin Koser; Bo Ying; Dongyu Chen; Xue Shui; Utsav Saxena; Wendy A Cyr; Anee Shah; Naim Nazef; Weimin Wang; Marc Abrams; Henryk Dudek; Eduardo Salido; Bob D Brown; Chengjung Lai
Journal:  Mol Ther       Date:  2016-01-13       Impact factor: 11.454

10.  Glyoxal formation and its role in endogenous oxalate synthesis.

Authors:  Jessica N Lange; Kyle D Wood; John Knight; Dean G Assimos; Ross P Holmes
Journal:  Adv Urol       Date:  2012-04-08
View more
  21 in total

1.  Crystal deposition triggers tubule dilation that accelerates cystogenesis in polycystic kidney disease.

Authors:  Jacob A Torres; Mina Rezaei; Caroline Broderick; Louis Lin; Xiaofang Wang; Bernd Hoppe; Benjamin D Cowley; Vincenzo Savica; Vicente E Torres; Saeed Khan; Ross P Holmes; Michal Mrug; Thomas Weimbs
Journal:  J Clin Invest       Date:  2019-07-30       Impact factor: 14.808

2.  Lactate dehydrogenase 5: identification of a druggable target to reduce oxaluria.

Authors:  Jacob S Stevens; Qais Al-Awqati
Journal:  J Clin Invest       Date:  2019-05-20       Impact factor: 14.808

3.  Endogenous Oxalate Production in Primary Hyperoxaluria Type 1 Patients.

Authors:  Sander Garrelfs; Dewi van Harskamp; Hessel Peters-Sengers; Chris van den Akker; Ronald Wanders; Frits Wijburg; Johannes van Goudoever; Jaap Groothoff; Henk Schierbeek; Michiel Oosterveld
Journal:  J Am Soc Nephrol       Date:  2021-10-22       Impact factor: 10.121

4.  Skin microvascular dysfunction as an early cardiovascular marker in primary hyperoxaluria type I.

Authors:  Alexandra Bruel; Justine Bacchetta; Tiphanie Ginhoux; Christelle Rodier-Bonifas; Anne-Laure Sellier-Leclerc; Bérengère Fromy; Pierre Cochat; Dominique Sigaudo-Roussel; Laurence Dubourg
Journal:  Pediatr Nephrol       Date:  2018-10-01       Impact factor: 3.714

5.  The effects of the inactivation of Hydroxyproline dehydrogenase on urinary oxalate and glycolate excretion in mouse models of primary hyperoxaluria.

Authors:  Brianna Buchalski; Kyle D Wood; Anil Challa; Sonia Fargue; Ross P Holmes; W Todd Lowther; John Knight
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-12-07       Impact factor: 5.187

6.  Plasma oxalate and eGFR are correlated in primary hyperoxaluria patients with maintained kidney function-data from three placebo-controlled studies.

Authors:  Dawn S Milliner; Pierre Cochat; Sally-Anne Hulton; Jerome Harambat; Ana Banos; Bastian Dehmel; Elisabeth Lindner
Journal:  Pediatr Nephrol       Date:  2021-01-30       Impact factor: 3.714

7.  Lanthanum carbonate to control plasma and urinary oxalate level in type 1 primary hyperoxaluria?

Authors:  Agnieszka Pozdzik; Cristina David; Jelle Vekeman; Frederik Tielens; Michel Daudon
Journal:  IJU Case Rep       Date:  2021-05-13

8.  Effect of alanine supplementation on oxalate synthesis.

Authors:  Kyle D Wood; Brian L Freeman; Mary E Killian; Win Shun Lai; Dean Assimos; John Knight; Sonia Fargue
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-09-28       Impact factor: 5.187

Review 9.  Nutrition and Kidney Stone Disease.

Authors:  Roswitha Siener
Journal:  Nutrients       Date:  2021-06-03       Impact factor: 5.717

Review 10.  Future treatments for hyperoxaluria.

Authors:  Zachary Burns; John Knight; Sonia Fargue; Ross Holmes; Dean Assimos; Kyle Wood
Journal:  Curr Opin Urol       Date:  2020-03       Impact factor: 2.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.